Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system.
Roshanthi Weerasinghe(Providence College), Brian Piening(Providence College), Josiah T. Wagner(Unknown), Bela Bapat(Illumina (United States)), Mark Schmidt(Cancer Institute (WIA)), Stanley Piotrowski(Providence Portland Medical Center), Lauren Harold(Providence Portland Medical Center), Brock E. Schroeder(Illumina (United States)), Phillip G. Febbo(Veracyte (United States)), Carlo Bifulco(Providence Health & Services), Thomas Ward(Providence Portland Medical Center), Ann Vita(Providence Portland Medical Center), Shu‐Ching Chang(Providence College), Alexa K. Dowdell(Providence Portland Medical Center), Alisha Stein(Illumina (United States)), Ryan Meng(Providence Portland Medical Center)
Cited by 1
Related Papers
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
|Nature Medicine|2004|956
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803